Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 17/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902946 | 1.00 | MEN1 (0.45) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL901914 | 0.74 | TRPM5 (0.47) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL901478 | 0.74 | TRPM5 (0.47) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL2136749 | 0.74 | TRPM5 (0.47) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL896940 | 0.74 | TRPM5 (0.47) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL10086286 | 0.73 | PDE10A (0.49) | PDE10A | |
| SCHEMBL901926 | 0.70 | PDE10A (0.49) | MEN1KMT2APDE10AMAPK1 | |
| SCHEMBL16278801 | 0.69 | KMT2A (0.46) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL16278799 | 0.69 | KMT2A (0.46) | MEN1PRNPKMT2APDE10ACYSLTR2 | |
| SCHEMBL16283539 | 0.69 | KMT2A (0.46) | MEN1PRNPKMT2APDE10ACYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621926-B1 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2621926-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| WO-2012044562-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | PDE12, PDE5A, PDE4A | MEN1 4648/4885PRNP 514/4885KMT2A 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.